[HTML] sciencedirect.com

[HTML][HTML] Real-world experience with CPX-351 in high-risk acute myeloid leukemia

RM Lemoli, P Montesinos, A Jain - Critical reviews in oncology/hematology, 2023 - Elsevier
Abstract CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
被引用次数：7 相关文章

Real-world experience with CPX-351 in high-risk acute myeloid leukemia

RM Lemoli, P Montesinos… - Critical reviews in …, 2023 - pubmed.ncbi.nlm.nih.gov
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved
for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …

Real-world Experience With CPX-351 in High-risk Acute Myeloid Leukemia.

RM Lemoli, P Montesinos, A Jain - Critical Reviews in Oncology …, 2023 - europepmc.org
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved
for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
[PDF] haematologisktidsskrift.dk

[PDF][PDF] Real-world experience with CPX-351 in high-risk acute myeloid leukemia

RM Lemoli, P Montesinos… - Critical Reviews in …, 2023 - haematologisktidsskrift.dk
ABSTRACT CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …